Your browser doesn't support javascript.
loading
Progress of OX40 and its ligand in lymphoma immunotherapy / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma ; (12): 371-375, 2019.
Article em Zh | WPRIM | ID: wpr-751409
Biblioteca responsável: WPRO
ABSTRACT
OX40 is a member of the tumor necrosis factor receptor (TNFR) superfamily. In the immune response of the body, OX40 and the OX40 ligand (OX40/OX40L) on the antigen-presenting cell membrane are important co-stimulatory molecules, which can promote the proliferation of T cells. And OX40 also has the dual role of activating and enhancing the T cell immune response. OX40/OX40L is an important target for tumor immunotherapy, and clinical studies of several OX40 agonists are currently underway. This article reviews the immunoregulatory mechanisms of OX40/OX40L and its research progress in lymphoma immunotherapy.
Palavras-chave
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Journal of Leukemia & Lymphoma Ano de publicação: 2019 Tipo de documento: Article
Texto completo: 1 Índice: WPRIM Idioma: Zh Revista: Journal of Leukemia & Lymphoma Ano de publicação: 2019 Tipo de documento: Article